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In normal healthy cells phosphatidylserine is located in the inner leaflet of the plasma membrane. However, on activated platelets, dying cells and
under specific circumstances also on various types of viable leukocytes phosphatidylserine is actively externalized to the outer leaflet of the plasma
membrane. Annexin A5 has the ability to bind in a calcium-dependent manner to phosphatidylserine and to form a membrane-bound two-dimensional
crystal lattice. Based on these abilities various functions for extracellular annexin A5 on the phosphatidylserine-expressing plasmamembrane have been
proposed. In this review we describe possible mechanisms for externalization of annexin A5 and various processes in which extracellular annexin A5
may play a role such as blood coagulation, apoptosis, phagocytosis and formation of plasmamembrane-derivedmicroparticles.We further highlight the
recent discovery of internalization of extracellular annexin A5 by phosphatidylserine-expressing cells.
© 2008 Elsevier B.V. All rights reserved.Keywords: Annexin A5; Phosphatidylserine; Plasma membrane; Microparticle; Exocytosis; Endocytosis1. Introduction
The annexins are a family of membrane binding proteins that
share structural properties and biological activities associated
with membrane related processes [1]. Each annexin consists of a
core structure of four domains of 70 amino acids with the
exception of annexin A6 which consists of two core structures
connected via a short peptide linker [2]. Members of the annexin
family are able to bind to negatively charged phospholipids in the
presence of Ca2+-ions. The physiological significance of the
individual members and the family as a whole is still poorly
understood but is envisioned to be linked predominantly to in-
tracellular processes [1].⁎ Corresponding author. Department of Biochemistry, Cardiovascular
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doi:10.1016/j.bbamcr.2008.01.030Annexin A5 is amongst the annexins that have extracellular
presence in addition to intracellular localization. Annexin A5
binds with high affinity tomembranes bearing phosphatidylserine
(PS). Over the past decade annexin A5 has been investigated as a
Molecular Imaging agent to visualize PS-expressing apoptotic
cells in vitro and in vivo in animal models and in patients [3]. The
clinical imaging procedure includes injection of human recombi-
nant annexin A5 into the patient's circulation. Understanding of
the biological significance of extracellular annexin A5 is of great
importance in the light of these developments.
Annexin A5 as well as annexins A1, A2 and A4 do not have
a 5′-leader sequence, which is necessary for release into the
extracellular environment. In this review we highlight calcium-
dependent phospholipid binding properties of annexin A5 and
describe briefly some of the mechanisms that have been put
forward to explain the presence of leaderless proteins on the cell
surface and in the circulation. We further describe on what cell
types and under which circumstances cell surface-expression of
PS occurs. We finally consider various functions of extracellular
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and to form a two-dimensional crystal lattice.
2. Properties of membrane-bound annexin A5
Annexin A5 is a protein of 35.7 kDa that binds in a calcium-
dependent and reversible manner to PS-expressing membranes
[4]. The tertiary structure of the soluble form of annexin A5 has
been solved with X-ray crystallography by Huber et al. [5]. X-ray
crystallography has revealed that the tertiary structure of annexin
A5 consists of a core of four domains that are arranged in a cyclic
array. This arrangement gives the molecule a slightly curved
shapewith a convex and a concave face. The Ca2+ and PS binding
sites are located at the convex, membrane-facing side of the
protein [6]. A short amino terminal tail is located at the concave
side of the molecule. The domains within the annexin A5
molecule interact with each other via non-covalent interactions.
The interdomain interactions result in the formation of two tightly
associatedmodules consisting of domains I and IVand domains II
and III. The interaction between domain I and IV is mediated in a
non-covalent manner by the amino-terminal tail. Domain II and
III are covalently linked via a short inter-helical turn.
It has been proposed, on the basis of fluorescence recordings of
a tryptophan residue located in domain III, that annexin A5
changes conformationwhen it binds to a PS-expressingmembrane
[7]. However, data obtained by electron crystallography indicated
that the membrane-bound form of the annexin A5 monomer has
nearly the same structure as the soluble form [8]. This means that
the membrane-bound form has a convex shape at the side
containing the phospholipid binding sites. This also indicates that
the various domains of the annexin A5 molecule have an unequal
distance to the membrane surface assuming that the surface is not
bent. Both electron crystallographic data and atomic force
microscopy suggest that domain III is the most distant from the
membrane surface and domain II the closest [8,9]. The convex
shape of membrane-bound annexin A5 potentially influences the
shape of the PS-expressing membrane. All four domains contain
calcium binding motifs making it possible that membrane-bound
annexin A5 influences the PS-expressing membrane surface to
adopt a shape that is complementary to the convex shape of the
annexin A5 molecule [8].
Electron crystallography of membrane-bound annexin A5 has
demonstrated that annexin A5 molecules can associate with each
other via protein–protein interactions [10]. In solution annexin A5
molecules are monomers, but upon binding to a PS-expressing
membrane they self-assemble into trimers followed by the for-
mation of a two-dimensional crystal lattice (Fig. 1A–C). Fig. 1A
shows that each annexin A5 molecule in the trimer is oriented in
such amanner that domain II is localized on the inside and domain
III and IVat the outside [11]. This ordering of individual annexin
A5 molecules within the trimer has consequences for the overall
shape of the trimer. The membrane facing side of the trimer is
closest to a flat membrane surface at its center and themost distant
at the outside. This means that the overall shape of the membrane-
facing side of the trimer is also convex. It was further dem-
onstrated that the annexinA5 trimer is the basic building block of a
two-dimensional crystal lattice. Fig. 1B shows that trimers as-sociate with each other into a two-dimensional lattice via inter-
actionsmediated by amino acid residues located on domain III [9].
The two-dimensional crystal lattice consists of trimers, dimers of
trimers and trimers of trimers arranged in a low-density and high-
density form with p6 and p3 symmetry respectively. The type of
two-dimensional crystal that is formed depends on the PS content
in the membrane and the calcium concentration. The low-density
P6 crystal, shown in Fig. 1C, predominantly forms onmembranes
with low PS content (b25 mol% PS). P6 crystals can convert into
high-density P3 crystals with a rate that increases with increasing
PS content and calcium concentration [12]. Whether annexin A5
crystallizes on a PS-expressing cell surface has yet to be
established. If it does it is expected to do so in the high-density
P3 form since it is believed that the PS-expressing membrane
patch has a high PS content.
3. Calcium and phosphatidylserine binding properties of
annexin A5
The ionized calcium concentration, [Ca2+] in the circulation,
which is approximately 1000 µmol/L, favors a rapid binding of
annexin A5 to cell surface-expressed PS. Binding of annexin
A5 to membranes that contain PS such as apoptotic and necrotic
cells occurs in a cooperative manner with respect to calcium
[13]. Ellipsometric measurements showed that PS-binding of
extracellular annexin A5 readily occurs when the membrane
contains a low mole fraction of PS [4]. The [Ca2+]1/2 at half
maximal binding of annexin A5 on a phospholipid layer con-
sisting of 5 mol% PS/95 mol% phosphatidylocholine (PC) and
20 mol% PS/80 mol% PC was shown to be 1500 and 220 µmol/
L respectively. Phospholipid binding of annexin A5 is not only
determined by PS content but also by the presence of other
phospholipids such as phosphatidylethanolamine (PE). It has
been observed that the minimal mole fraction PS necessary for
annexin A5 binding decreases in the presence of PE [14]. This
indicates that annexin A5 binding to PS depends on calcium
concentration as well as on the environment of PS.
Zinc ions appear to affect the calcium-dependent binding of
annexin A5 to PS-expressing membranes [4]. Zinc ions alone are
not sufficient to promote annexin A5 binding to PS-expressing
membranes. Instead, zinc ions augment calcium induced binding
probably by increasing affinity of annexin A5 for PS. This phe-
nomenon has been attributed to annexin A5's cysteine residue
located at amino acid position 315 in the C-terminal tail (Reuteling-
sperger, unpublished data). Possibly a zinc ion associates with the
cysteine-315 residue thereby influencing the calcium-dependent
binding affinity of annexin A5. Zinc ions are present in the cir-
culation at a concentration of 12–16 µmol/L [15] and may enhance
binding affinity of annexin A5 for PS-expressingmembranes when
annexin A5 is present in the circulation.
4. Unconventional secretory pathways of annexins
Annexins are considered cytosolic proteins because they lack a
5′-leader sequence in their messenger RNA. However, annexins
A1, A2, A4 and A5 have been found on the cell surface and in the
circulation indicating that they are released into the extracellular
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compartment contain a leader sequence in their messenger RNA
that directs them to the endoplasmatic reticulum (ER) [21].
Synthesized protein is then transported via the Golgi apparatus to
the plasma membrane and subsequently into the extracellular
environment. A possible explanation for the presence of annexins
in the circulation might be the release of cytosolic content from
necrotic cells into the surrounding environment. There are how-
ever indications for the existence of specific protein release
pathways independent of the ER and Golgi apparatus. For in-
stance interleukin-1β, galectins and fibroblast growth factor
(FGF-1 and -2) are proteins that lack a 5′-leader sequence and yet
they are released into the circulation [22–29]. These so called
unconventional secretory pathways are characterized by their
insensitivity to inhibitors of ER/Golgi-dependent secretory trans-
port such as brefeldin A and monensin. Several unconventional
secretory pathways have been proposed to exist. Internleukin-1βFig. 1. Trimer and two-dimensional crystal formation. (A) Membrane-bound annexin
each individual annexin A5 molecule is located in the center of the trimer. (B) Two-dim
electron crystallography images. The connection between trimers, mediated by domai
from Prof. A. Brisson and Elsevier. (C) On a membrane surface with a PS content th
followed by the formation of a two-dimensional crystal lattice described by P6 symis suggested to be released via the plasma membrane located
ABC-A1 transporter, secretory lysosomes, exosomes or by shed-
ding of interleukin-1β-containing plasma membrane-derived mi-
croparticles [22–26]. Similar to interleukin-1β, release of galectins
into the extracellular environment is also suggested to occur via
shedding of plasma membrane-derived microparticles [27]. It is
reported that release of FGF-1 is mediated by a cytosol located
multi-protein complex comprised of Cu2+, S100A13, synapto-
tagmin-1 p40 and FGF-1 [28]. Complex formation occurs near the
inner leaflet of the plasma membrane which contains PS. The PS
binding properties of FGF-1, S100A13 and synaptotagmin-1 p40
make it possible that these proteins form a complex near the inner
leaflet of the plasma membrane. How this multi-protein complex
is translocated across the plasma membrane is at present unclear.
Currently available data suggest that FGF-2 is released via a
mechanism distinct from FGF-1. Release of FGF-2 occurs di-
rectly at the plasma membrane and is linked to the presence ofA5 assembles into a trimer which is organized in such a manner that domain II of
ensional projection map of membrane-bound annexin A5 calculated from cryo-
n III, is indicated with the red arrow. Image reprinted from [117] with permission
at matches the PS content found on biological membranes trimer assembling is
metry.
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[29–31]. It was recently shown that release of FGF-2 is prevented
if mutations were introduced in its HSPGs binding domain [31].
Release of annexins has also been proposed to occur via un-
conventional secretory pathways. Extracellular annexin A1 func-
tions in anti-inflammatory processes by regulating adhesion and
transmigration of leukocytes at sites of inflammation [32–34].
Annexin A1 is released by neutrophils and pituitary folliculo-
stellate cells [32,35]. Release of annexin A1 from pituitary
folliculo-stellate cells occurs when these cells are treated with the
glucocorticoid dexamethasone [35]. Treatment of pituitary gland-
derived cells with brefeldin A and monensin does not prevent
release of annexin A1 indicating that release occurs via an
unconventional secretory pathway [36]. Release of annexin A1
occurs after serine-phosphorylation and has been proposed to be
mediated by the ABC-A1 transporter [37,38]. Extracellular an-
nexin A2 has been reported to function as a cell surface receptor for
plasminogen on endothelial cells [39,40]. It is suggested that
annexinA2 is released by endothelial cells after stimulation of these
cells with thrombin [41]. In addition, it was shown that endothelial
cells subjected to a brief period of temperature stress also trans-
locate annexin A2 to the cell surface [42]. Temperature stress-
induced translocation of annexinA2 depends on both expression of
S100A10 and tyrosine phosphorylation of annexin A2. Depletion
of S100A10 andmutation of the tyrosine-23 residue of annexin A2
abrogated its translocation to the surface [42]. The mechanism
underlying annexin A2's translocation across the plasma mem-
brane to the cell surface is currently not clear.
The circumstances under which annexins A4 and A5 are
released into the circulation have been less thoroughly investi-
gated. It has been suggested that during pregnancy both proteins
play a role in the extracellular placental compartment in contact
with maternal blood. Annexin A5 is localized on the apical
surface of all syncytiotrophoblasts whereas annexin A4 resides at
the basolateral side of some syncytiotrophoblasts [18,43]. An-
nexin A5 plasma concentration remains low and constant during
pregnancy and post-partem. Oppositely, annexin A4 plasma levels
increase significantly shortly after delivery indicating different
regulatory mechanims for the two annexins [18]. It has further
been reported that annexin A5 is released during apoptosis of
cardiomyocytes and THP-1 macrophages [44,45]. The mech-
anisms responsible for release of annexins A4 and A5 have not
been investigated.
5. Regulation of membrane phospholipid asymmetry
In vitro studies indicated that, once released into the circulation,
annexin A5 potentially plays a role in various biochemical and
cellular processes occurring on PS-exposing membranes. Since
annexin A5 binds to plasma membranes when PS is present in the
exofacial membrane leaflet it is of some interest to describe which
cell types and under which circumstances cell surface expression
of PS occurs. The plasma membrane consists of a phospholipid
bilayer containing charged and uncharged phospholipid species.
Aminophospholipids such as the negatively charged PS and
positively charged PE reside predominantly in the inner leaflet
facing the cytosol [46]. There PS is believed to be involved inregulating membrane charge and protein localization at cytosol
facing membrane leaflets [47].
Uncharged aminophospholipids, such as PC and sphingomyelin
(SM) reside both in the inner and outer leaflet (PC) or pre-
dominantly in the exofacial leaflet (SM) [46]. Normal healthy cells
actively generate and maintain phospholipid asymmetry of the
plasma membrane. Under certain circumstances cells can induce a
change in PS asymmetry by translocating PS to the exofacial leaflet
of the plasma membrane. This occurs for example in activated
platelets adhering to collagen, ageing erythrocytes and nucleated
cells executing apoptosis [46,48,49]. Recent studies have shown
that loss of membrane asymmetry in nucleated cells is not uniquely
associated with apoptosis. Living cells can also express PS at their
surface independent of cell death. For instance monocytes dif-
ferentiating into macrophages and a subpopulation of T-lympho-
cytes expose PS [50,51]. Cell surface expression of PS can also
occur after stimulation of monocytes and neutrophils with the
β-galactoside-binding proteins galectin-1, -2 and -4 [52,53]. In
addition, throphoblasts differentiating into a placental syncytio-
trophoblast and myoblasts fusing into myotubes express PS
[54–56]. The claim that living, positively selected, B-cells express
PS on the cell surface has been disputed [57,58]. It was shown that
PS-expression on B-cells only occurs ex vivo and not in vivo [58].
It is thought that activemaintenance of phospholipid asymmetry
is carried out by intrinsic membrane proteins. Several transporters
have been postulated to exist [46,59]. Inward translocation is
mediated by the aminophospholipid translocase. Translocation is
ATP-dependent and specific for PS andwith a lesser efficiency also
for PE. A sustained rise in cytosolic Ca2+ concentration causes
inactivation of the inward translocation process. A P-type ATPase
has been identified as a putative aminophospholipid translocase
[60]. Scramblase is an anti-porter that translocates phospholipids
from the outer leaflet to the inner leaflet and vice versa. Trans-
location is ATP independent and occurs after sufficient and sus-
tained rise in cytosolic Ca2+ concentration. It was proposed that
members of the gene family known as the phospholipid scramblase
family are responsible for bi-directional translocation of phospho-
lipids [61,62]. Recent experiments have cast doubt on this claim
because a phospholipid scramblase-1 knockout mouse showed no
defects in PS-expression and blood coagulation [63]. Outward
translocation of phospholipids is carried out by ABC-C1, a mem-
ber of the multi drug resistance (MDR) protein family [64,65].
Recently, it was shown that in C. elegans the aminophospholipid
translocase TAT-1 is involved in PS-expression during the early
stages of apoptosis [66]. Cell surface exposure of PS can arise from
simultaneous inactivation of aminophospholipid translocase and
activation of scramblase. This has been demonstrated for activated
platelets and apoptotic cells [67,68]. The intracellular pathways
involved in the inactivation of the aminophospholipid translocase
and the activation of scramblase andABC-C1 aremostly unknown.
PS-expression on the surface of dying cells is dependent on active
caspase 3 during Fas-ligand-induced cell death and active
cathepsin B during TNF-α-induced cell death [69,70]. In which
way caspase 3 and cathepsin B (in)activate phosphoplipid trans-
location is at present unclear. It is thought that caspase 3 and
cathepsin B act on intermediate proteins which are responsible for
(in)activation of phospholipid translocation proteins. The pathways
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are currently unknown.Recently it was proposed thatmassiveCa2+
release from endoplasmic reticulum and mitochondria causes inac-
tivation and activation of translocase and scramblase respectively.
Ca2+ release from intracellular storeswas accomplished via caspase
dependent and independent pathways [71]. Given the reported
reversibility of inactive translocase and active scramblase this
provides amechanistic explanation for reversible PS-expression by
living cells. Nagata and co-workers postulated the hypothesis that
PS-expression on living lymphocytes and macrophages results
from binding of PS-bearing exosomes to the newly described PS-
receptors TIM-1 and TIM-4. This presents an alternative
explanation for PS exposure independent from regulation of PS
asymmetry [72].
6. Functions of extracellular annexin A5
6.1. Annexin A5 inhibits the formation of the prothrombinase
complex
The capacity of annexin A5 to bind calcium-dependently to
PS has lead to the proposal that annexin A5 plays a role in the
anti-thrombotic arm of blood coagulation [73,74]. Loss of vessel
wall integrity due to vascular injury is one of the factors that can
trigger activation of the blood coagulation process. The initial
response to vascular injury is formation of a platelet plug by
adhesion and activation of platelets to collagen-exposed sites on
the vessel wall [75]. Platelet adhesion to collagen triggers
expression of PS on the membrane surface of platelets [48].
Platelet-expressed PS supports assembly of the prothrombinase
complex composed of factor Va (FVa), factor Xa (FXa) and
prothrombin [76]. The prothrombinase complex subsequently
converts the zymogen prothrombin into proteolytically active
thrombin [77]. Thrombin in turn converts fibrinogen into fibrin
polymers that stabilize the platelet plug on the damaged vessel
wall [78]. Annexin A5 competes with FVa, FXa and prothrombin
for binding to PS thereby preventing formation of the pro-
thrombinase complex and consequently formation of thrombin
[79]. Alternatively it was proposed that annexin A5 inhibits
thrombin generation by forming a two-dimensional lattice on the
PS-expressing surface [80]. This lattice does not fully block binding
of coagulation factors but inhibits formation of prothrombinase
complex by preventing lateral movement of PS-bound FVa, FXa
and prothrombin.
It was proposed that the anticoagulant activity of annexin A5
plays a role in preventing thrombotic processes that occur on
placental villi in contact with maternal blood [81]. During
placental development trophoblasts fuse to form syncytiotro-
phoblasts, a multinucleated syncytium with a brush border in
contact with maternal blood [82]. Syncytiotrophoblast forma-
tion is accompanied by cell surface-expression of PS making
the syncytium a potential site for activation of coagulation
processes [54,55]. Annexin A5, which is abundantly present on
the syncytial surface, prevents coagulation processes by
forming a two-dimensional lattice [43,81]. Anti-phospholipid
antibodies can disrupt the organization of the annexin A5 two-
dimensional lattice [83]. This mechanism could contribute tothe increased risk for recurrent pregnancy that woman with
antiphospholipid antibody syndrome experience [84].
6.2. Annexin A5 and its role on the surface of apoptotic cells
Damaged, senescent or unwanted cells turn into apoptosis, an
abundant form of programmed cell death [85]. Apoptosis is
characterized by various biochemical and cellular changes in the
cytosol and on the cell surface. Intracellular changes include for
instance activation of proteolytic enzymes known as caspases
[86]. Activation of one of the caspases, caspase 3, causes various
changes on the cell surface such as expression of PS and
generation of microparticles [69,87,88]. Cell surface-expressed
PS on apoptotic cells serves as an “eat me” signal for phagocytes
such as macrophages [46,89]. PS on apoptotic cells has also an
important role in suppression of auto-immune response against
self-antigens of the phagocytosed dying cell [72,90]. The im-
munoregulatory activity of PS likely arises from its ability to
modulate cytokine production by the engulfing phagocyte [91].
PS triggers phagocytosis through activating PS receptors on
the macrophage directly or by binding bridging molecules such
as MFG-E8, beta-2-glycoprotein 1 and annexins A1 and A2
[72,92–94]. AnnexinA5 does not function as a bridgingmolecule
like annexins A1 and A2. It has been found that annexin A5
inhibits phagocytosis of dying cells [95]. Inhibition most likely
occurs through shielding of cell surface-expressed PS and inter-
nalization of the PS-expressing membrane patch that putatively
harbours other “eat me” signals besides PS. It is proposed that
both inhibitory mechanisms involve the 2D-crystallisation of
annexin A5 at the cell surface. It is of interest to note that inhi-
bition of phagocytosis requires a high concentration of annexin
A5 [95]. Munoz et al. proposed that annexin A5 plays a role
in vivo in the modulation of the immune system by inhibiting
phagocytosis of apoptotic and necrotic cells [96]. They observed
that necrotic cells introduced into the circulation ofwild typemice
caused a strong, allogeneic delayed-type hypersensitivity (DTH)
reaction. In contrast when necrotic cells were introduced in
annexin A5 knock out mice that lacked endogenous annexin A5
this DTH reaction was almost absent.
In addition to inhibiting phagocytosis of the apoptotic cell it has
also been reported that binding of annexin A5 to the apoptotic cell
surface influence progression of the apoptotic cell death program.
On the one hand, annexin A5 delays activation of caspase 3 after
binding to the cell surface of human CEM T-lymphoma cells
treated with a cytostatic agent [97]. On the other hand, annexin
A5 accelerates the cell death program of peroxide-treated dying
rat cardiomyocytes [44]. Progression of the cell death program
was delayed in the presence of anti-annexin A5 antibodies or
after removing of annexin A5 from the cell surface. Annexin
A5 binding to Fas-stimulated human Jurkat T-lymphoma cells
has, however, no effect on progression of the apoptotic program
[98]. Taken together the reported results indicate that the effect
of cell surface binding of annexin A5 on execution of cell death
depends on cell type and trigger to activate the cell death
program. It has to be noted that effects, if observed, occurred only
upon co-incubation of cells with the cell death inducing trigger
and annexin A5.
Fig. 2. Annexin A5 inhibits microparticle formation. Stimulated platelets and
apoptotic cells that express PS on the cell surface shed plasmamembrane-derived
microparticles. Annexin A5 is able to inhibit the formation of microparticles by
these cells. Inhibition of microparticle formation occurs by monomeric annexin
A5 and is dependent on its capacity to bind ionized calcium and PS.
958 H.O. van Genderen et al. / Biochimica et Biophysica Acta 1783 (2008) 953–9636.3. Inhibition of microparticle generation by annexin A5
Microparticles (MPs) are plasma membrane-derived vesicles,
ranging in size from 0.05 to 1 µm, shed from stimulated cells [99].
Shedding of plasma membrane-derivedMPs was reported as early
as 1982 [100]. It was demonstrated that platelets stimulated with
thrombin or collagen actively shed MPs. Circulating MPs are
implicated in a variety of diseases including atherosclerosis, cancer
and auto-immune disorders [101]. MPs can be involved in various
ways. Recent insights suggest that MPs function in intercellular
communication processes. Leukocytes shed for instance hedge-
hog- and interleukin-1β-containing MPs [26,102]. MPs are also
implicated in transfer of plasmamembrane receptors between cells
[103–108]. It was demonstrated that stimulated peripheral blood
mononuclear cells actively shed MPs containing the chemokine
receptor CCR5 [108]. CCR5-containing MPs were shown to be
accepted by CCR5-negative endothelial cells which subsequently
expressedMP-derived CCR5 on the cell surface. MPs may also be
involved in thrombotic disorders by expressing tissue factor and
PS [104–106,109] on their surface. The presence of PS on MPs
is sufficient to promote annexin A5 binding [110]. Annexin A5
binding inhibits the procoagulant activity of PS bearingMPs [111].
In addition, annexin A5 appears to restrict dose dependently
generation of platelet and apoptotic T-lymphoma cell-derived PS-
expressing MPs (Fig. 2) [97,98,112]. Inhibition of MP generation
is believed to be the result of annexinA5 binding to and subsequent
two-dimensional-crystallization at the surface of the PS-expressing
and MP generating cell [97]. It is suggested that the annexin A5
lattice acts as a physical constraint counteracting blebbing and
shedding of MPs from the plasma membrane. However, annexin
A1, which binds PS but does not form a two-dimensional crystal
lattice [113], also inhibits MP generation although with a lesser
efficiency (Reutelingsperger unpublished data). Another mechan-
istic explanation is that annexin A5 inhibits MP formation by
forming Ca2+-conducting ion channels in the plasma membrane.
Annexins are thought to conduct Ca2+-ions across the plasma
membrane by inserting into the lipid bilayer [114–118]. During
insertion the annexin B12 and annexin A5molecule is proposed to
change conformation so that these proteins traverse the entire
bilayer in such a manner that ions are able to cross the membrane
[117]. According to current models annexin A5 insertion into the
plasmamembrane occurs in amildly acidic environment and in the
presence of peroxide at low Ca2+ concentrations [117,118]. Con-
ditions that satisfy these requirements are found in the cytosol and
not in the extracellular environment. Because of prevalent extra-
cellular Ca2+ concentrations it is unlikely that extracellular annexin
A5 inhibits MP formation through Ca2+ ion channel activity.
Alternatively, annexin A5 may inhibit MP formation via a
signal transduction pathway after interacting with a cell surface-
expressed protein. Recently, it was reported that extracellular
annexin A5 binds via its N-terminal tail to cell surface
expressed polycystin-1 [119]. This interaction is not dependent
on annexin A5's ability to bind PS. Consequently, interaction of
annexin A5 with polycystin-1 does not explain inhibition of MP
generation. It cannot be excluded, however, that other plasma
membrane proteins chaperone annexin A5's ability to restrict
MP formation.To date it remains to be established that annexinA5 inhibitsMP
generation in vivo. The likelihood of such in vivo ability probably
depends on annexin A5 concentration in the vicinity of MP gen-
erating cells. AnnexinA5 concentration at which inhibition ofMP
generation occurs is approximately 100 nmol/L (Kenis, unpub-
lished data). The concentration of annexin A5 in the circulation is
approximately 1.5 nmol/L suggesting that annexin A5 does not
play a significant role in inhibiting MP generation [19,20]. How-
ever, annexin A5 may reach higher levels locally at sites of its
release.
7. A novel endocytic pathway induced by annexin A5
Recent studies showed that annexin A5 is internalized into the
cytosol by stressed cardiomyocytes (Reutelingsperger, manu-
script in preparation), myoblasts and apoptotic neurons [56,120].
The endocytic pathway responsible for annexin A5 internaliza-
tionwas however not investigated in these studies. Endocytosis of
proteins present in the extracellular environment occurs via
macropinocytosis or receptor-mediated internalization [121].
Kenis et al. demonstrated that annexin A5 internalization by
apoptotic Jurkat cells and viable PS-expressing HeLa tumor cells
is independent from these endocytic pathways [98]. Internaliza-
tion appears to be dependent on binding of annexin A5 to PS.
Since annexin A1 binds to PS-expressing cells without being
internalized it was concluded that PS binding by itself is
insufficient to explain internalization. It was hypothesized that
bound annexin A5 forms trimers that associate into a lattice that
causes invagination of the PS-expressing membrane patch
followed by endocytosis and intracellular trafficking of the
endocytic vesicle [98]. Annexin A5 molecules do not signifi-
cantly change conformation after binding to PS-expressing
membranes and organizing into trimers. Hence, PS-bound
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binding side [8]. Based on these considerations and that the PS-
expressing membrane patch is flexible it was hypothesized that
the PS-expressing membrane adopts a shape that is complemen-
tary to the convex shape of the membrane facing side of the
annexin A5 trimer. The individual trimers moving unconnected to
each other across the cell surface are probably not able to induce
inward membrane bending. However nucleation and subsequent
two-dimensional crystallization of trimers might focus membrane
bending into vesicle formation. The site of nucleation of the two-
dimensional crystal acts as a focal point in the membrane bending
process that leads to formation of the vesicle (Fig. 3). Support for
this hypothesis was provided by experiments with M23, a mutant
of annexin A5 that possesses defective calcium binding sites in
domain II and III. M23 remains localized to the cell surface
without being internalized. Due to the defective calcium binding
sites in domain II and III, M23 is likely not able to adopt mem-
brane curvature to the convex shape of the annexin A5 molecule.
In addition, it was shown that M23 does not form a two-
dimensional lattice. Further support came from annexinA1,which
does not form a two-dimensional crystal lattice when bound to PS-
containing membranes. Annexin A1 is also not internalized.
However, co-incubation of apoptotic Jurkat and viable HeLa cells
with annexin A1 and A5 results in uptake of both annexins in the
same endocytic vesicles [98].
It was suggested that the annexin A5 endocytic pathway
internalizes extrinsic and intrinsic proteins in the vicinity of cell
surface-expressed PS. The latter was demonstrated for tissue
factor (TF) on apoptotic THP-1 macrophages [45]. TF is the cell
surface receptor of the serine protease factor VIIa. TF complexed
with factor VIIa is considered to be involved in the initiation of
the coagulation cascade by converting inactive factor X intoFig. 3. Annexin A5 and phosphatidylserine dependent endocytosis. Internalization
dependent on the convex shape of the membrane-facing side of the annexin A5 trim
Endocytosis occurs via the following steps: PS binding of annexin A5 (1) is follo
membrane (2) and endocytic vesicle formation (3). Fission of vesicles from the plasactive factor Xa [75]. It was shown that annexin A5-induced
internalization of TF on apoptotic THP-1 cells resulted in sig-
nificant decrease of TF activity [45]. This prompted the proposal
that annexin A5 inhibits coagulation not only by shielding the PS
surface but also by internalizing the PS-expressing membrane
patches carrying procoagulant factors such as TF. This example
may represent a more general mechanism of annexin A5 induced
down-regulation of surface expressed receptors in PS bearing
membrane patches [45, 95].
8. Concluding remarks
Annexin A5 has gained broad attention over the last decade
because of its use as a Molecular Imaging agent to measure
apoptosis in vitro and in vivo in animal models and in patients [3].
Understanding the (patho)physiological significance of extra-
cellular annexin A5 is of great importance in the light of these
developments. Knock-out animal models have shed little light on
annexin A5's physiological significance sofar [122]. Also, no
human pathology has been causally connected to aberrations in
annexin A5 genomics and proteomics to date. Current literature
harbours a wealth of data about physicochemical and biological
properties of annexin A5. Based hereon we assume that annexin
A5 has more than one physiological function. Which one is
actually exhibited depends likely on localization and local con-
centration. In this survey we considered possible functions for
annexin A5 in the extracellular compartment based on its ability
to bind PS and to form a two-dimensional lattice on the PS-
expressing membrane. Annexin A5 can thus play various roles in
apoptosis, haemostasis and thrombosis, inflammation and im-
munology by shielding PS surfaces, inhibitingMPs formation and
down-regulating cell surface-expression of receptors. Futureof membrane-bound annexin A5 by PS-expressing cells is hypothesized to be
er and on the ability of these trimers to form a two-dimensional crystal lattice.
wed by two-dimensional crystallization which causes bending of the plasma
ma membrane (4) occurs via an as-yet undetermined mechanism.
960 H.O. van Genderen et al. / Biochimica et Biophysica Acta 1783 (2008) 953–963research should provide more insight into the physiological sig-
nificance of extracellular annexin A5. Although it is important to
unveil its physiological significance, lack of immediate success in
this respect should not discourage future research efforts on
annexin A5. For example, the recent discovery of annexin A5
internalization opens novel avenues to exploit annexin A5 as a
targeting agent for delivery compounds into PS-expressing cells.
A similar spin-off from the research road towards physiological
significance has previously led to the successful development of
annexin A5 as a Molecular Imaging agent.
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